Musi waChikumi 29, 2017, kuvandudzwa kweLaipushutai, kirasi I yemishonga yekuvandudza nekubatana kwekuvandudza kweJYMed neGuangzhou Linkhealth Medical Technology Co., Ltd., yakafambira mberi zvakanyanya. Chiziviso chemushonga IND chatambirwa neCFDA.

JYMed neGuangzhou Linkhealth Medical Technology Co., Ltd. yakawana chibvumirano chekushandira pamwe muna 2016 chekugadzira pamwe chete chigadzirwa ichi muChina. Mhuka idzi dzakapedza zvidzidzo zvekiriniki zvePOC muEU uye dzakawana kuchengetedzwa kwakanaka uye mitengo yekuregererwa. Vese FDA neEMA vanocherechedza kuti mhuka iyi inogona kushandiswa kurapwa pamutsara weI/II, uye chinokosheswa chichaiswa mukuyamura uye kurapwa kwevarwere vane mwero ulcerative colitis mukutevera miedzo yekiriniki yeCFDA.

Ulcerative colitis (UC) chirwere chisingaperi, chisina-chaiyo chekuzvimba chinoitika murectum uye colon. Maererano nehuwandu, huwandu hwehuwandu hweUC ndeye 1.2 kusvika ku20.3 kesi / 100,000 munhu pagore uye kuwanda kweUC ndeye 7.6 kusvika ku246.0 kesi / 10,000 vanhu pagore. Chiitiko cheUC chinowanzoitika kune vechidiki vechidiki. Musika weUC une hukuru hukuru uye kudiwa kwemishonga, uye icharamba ichichengetedza yakakwira kukura mune ramangwana. Kusvika pari zvino, UC yekutanga-mushonga wemushonga unonyanya kubva pamesalazine nemahomoni, uye yechipiri-mutsara mishonga inosanganisira immunosuppressants uye biological monoclonal antibodies. Mesalazine ine chiyero chekutengesa che 1 bhiriyoni muChina uye US $ 2 bhiriyoni muUnited States mu 2015. Laipushutai ine mhinduro iri nani kune zviratidzo zveUC, uye yakachengeteka kudarika ikozvino mishonga yekutanga. Iyo ine mukana wakanaka wemusika uye inotarisirwa kuve yekutanga-mutsara UC mushonga.